New Breast Cancer Drug Cuts Side Effects by 50%

Nearly half of women over 40 have dense breasts, a condition that significantly increases breast cancer risk. Now, a new drug offers them hope with far fewer side effects than current prevention options.

The KARISMA trial tested endoxifen on 240 healthy premenopausal women in Sweden between 2021 and 2023. Researchers wanted to know if this drug could reduce dangerous breast density without the harsh side effects that make many women quit tamoxifen, the current standard treatment.

The results were remarkable. Women taking just 1 milligram of endoxifen saw their breast density drop by 19%, while those on 2 milligrams experienced a 26% reduction. That matches the effectiveness of tamoxifen's much higher 20 milligram dose.

But here's the game changer. Women on the lower 1 milligram dose reported fewer problems with diarrhea, vaginal bleeding, vision issues, breast tenderness, dry mouth, and weight loss compared to those taking a placebo. The higher dose caused more night sweats and hot flashes, but the lower dose didn't worsen symptoms at all.

Dr. Blen Tesfu, a medical advisor at Welzo who reviewed the findings, called them important for breast cancer prevention. The trial demonstrates that significantly lower doses can achieve the same protective effects with better tolerability.

The study was rigorous. Neither participants nor researchers knew who received which treatment until completion, eliminating bias. Specialized imaging tracked breast density changes over six months, while blood tests confirmed the drug was working as expected.

Why This Inspires

This breakthrough matters because treatment only works if women actually take it. Many women stop tamoxifen because the side effects disrupt their daily lives too severely. When prevention feels worse than the disease you're trying to avoid, compliance plummets.

Endoxifen could change that equation entirely. By delivering the same protection with a fraction of the side effects, it gives women a realistic option they can stick with long term. Better compliance means fewer women developing breast cancer in the first place.

The lower dose also showed a clear plateau effect at certain blood concentrations, suggesting doctors can prescribe the minimum effective amount. Less medication, same protection, fewer problems.

If further research confirms these results, endoxifen could become the new standard for breast cancer prevention, helping millions of women protect themselves without sacrificing their quality of life.